CX-2051 Momentum and An Expanding Oncology Pipeline Strengthen CytomX Therapeutics’ (CTMX) Investment Case
The Fly reported on November 11, 2025, that CytomX Therapeutics, Inc. (NASDAQ:CTMX)’s price target was raised from $5 to $10 by H.C. Wainwright’s Mitchell Kapoor.





